HealthYahoo Financeabout 4 hours ago
ATAI Beckley Poised for Clinical and Shareholder Value
1 min read
Atai Beckley N.V. (NASDAQ:ATAI) is a top penny stock to buy, according to the source. The company delivered solid first-quarter results and remains on track for the Phase 3 Pivotal program for BPL-003, a short-acting psychedelic. Topline Phase 2 results for VLS-01 are anticipated in the fourth quarter. The company holds $209.9 million in cash to advance clinical programs.
Level
Hype check
Tap to vote and see what everyone thinks.
